BioAsia 2023: Focus Research Outside US, Take ‘One Health’ Approach To Prevent Next Pandemic
Speakers from BMS, Takeda, UNICEF and more discussed how a shift in R&D focus, free flow of data on animal and human health, public sector investment and higher regulatory flexibility are key to make ‘One Health’ work and prevent future pandemics
You may also be interested in...
CEPI CEO On Tackling The Next Pandemic Threat, F1 Pit Stop Operational Excellence
BioAsia 2023: CEPI's CEO, Dr Richard Hatchett, talks about viruses with pandemic potential, enhanced ‘spillover risk’ and delivering on operational excellence to get to the mission of having vaccines ready for initial authorization within 100 days of identification of a pandemic pathogen.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 7: Clinical Trial Trends
From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.
Barrier For Applying AI To Precision Medicine: Drug Industry Reluctance To Share Data
Eric Topol says there is not enough regulatory teeth to require companies to share data with the medical community. Experts at a workshop on the application of artificial intelligence and machine learning for precision medicine also want data and algorithms to be accessible.